Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: a systematic review and meta-analysis of phase 3 randomized controlled trials

Poly(ADP-ribose) polymerase inhibitors (PARPi) have revolutionized cancer treatment in recent years [1]. Indeed, many PARPi have already been granted regulatory approvals, either as monotherapy or in combination with other agents, and consequently reached clinical practice, in the treatment of several solid tumors like ovarian, breast, pancreatic and prostate cancers [2 –5]. PARPi target the DNA damage response pathway, which plays a crucial role in maintaining genomic stability. Specifically, PARP enzymes are critical for repairing single-strand DNA breaks, which occur frequently during DNA replication.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Anti-tumour Treatment Source Type: research